Convalescent Adaptive Immunity is Highly Heterogenous after SARS-CoV-2 Infection

Optimal detection strategies for effective convalescent immunity after SARS-CoV-2 infection and vaccination remain unclear. The objective of this study was to characterize convalescent immunity targeting the SARS-CoV-2 spike protein using a multiparametric approach. At the beginning of the pandemic, between April 23, 2020, to May 11, 2020, we recruited 30 COVID-19 unvaccinated convalescent donors and 7 unexposed asymptomatic donors. Peripheral blood mononuclear cells (PBMCs) were obtained from leukapheresis cones. The humoral immune response was assessed by measuring serum anti-SARS-CoV-2 spike S1 subunit IgG semiquantitative ELISA and T cell immunity against S1 and S2 subunits were studied by IFN-γ Enzyme-Linked Immune absorbent Spot (ELISpot), flow cytometric (FC) activation-induced marker (AIM) assays and the assessment of cytotoxic CD8+ T-cell function (in the subset of HLA-A2 positive patients). No single immunoassay was sufficient in identifying anti-spike convalescent immunity among all patients. There was no consistent correlation between adaptive humoral and cellular anti-spike responses. Our data indicate that the magnitude of anti-spike convalescent humoral and cellular immunity is highly heterogeneous and highlights the need for using multiple assays to comprehensively measure SARS-CoV-2 convalescent immunity. These observations might have implications for COVID-19 surveillance, and optimal vaccination strategies for emerging variants. Further studies are needed to determine the optimal assessment of adaptive humoral and cellular immunity following SARSCoV-2 infection, especially in the context of emerging variants and unclear vaccination schedules.

[1]  A. Mann,et al.  Viral emissions into the air and environment after SARS-CoV-2 human challenge: a phase 1, open label, first-in-human study , 2023, The Lancet Microbe.

[2]  P. Møller,et al.  Do cytotoxicity and cell death cause false positive results in the in vitro comet assay? , 2022, Mutation research. Genetic toxicology and environmental mutagenesis.

[3]  A. Scheffold,et al.  Mycobacterium tuberculosis-specific CD4 T-cell scoring discriminates tuberculosis infection from disease , 2022, European Respiratory Journal.

[4]  D. Lewinsohn,et al.  The Missing Link in Correlates of Protective Tuberculosis Immunity: Recognizing the Infected Cell , 2022, Frontiers in Immunology.

[5]  E. Theel,et al.  Antigen Specific Humoral and Cellular Immunity Following SARS-CoV-2 Vaccination in ANCA-Associated Vasculitis Patients Receiving B-Cell Depleting Therapy , 2022, Frontiers in Immunology.

[6]  Jordan J. Clark,et al.  Activity of convalescent and vaccine serum against SARS-CoV-2 Omicron , 2021, Nature.

[7]  K. Kedzierska,et al.  T Cells Targeting SARS-CoV-2: By Infection, Vaccination, and Against Future Variants , 2021, Frontiers in Medicine.

[8]  T. Ndung’u,et al.  Omicron extensively but incompletely escapes Pfizer BNT162b2 neutralization , 2021, Nature.

[9]  Benjamin J. Polacco,et al.  Evolution of enhanced innate immune evasion by SARS-CoV-2 , 2021, Nature.

[10]  P. Maes,et al.  Considerable escape of SARS-CoV-2 Omicron to antibody neutralization , 2021, Nature.

[11]  Fei Shao,et al.  Omicron escapes the majority of existing SARS-CoV-2 neutralizing antibodies , 2021, bioRxiv.

[12]  Liyuan Liu,et al.  Striking antibody evasion manifested by the Omicron variant of SARS-CoV-2 , 2021, Nature.

[13]  B. Alarcón,et al.  Longitudinal dynamics of SARS-CoV-2-specific cellular and humoral immunity after natural infection or BNT162b2 vaccination , 2021, PLoS pathogens.

[14]  R. Lins,et al.  SARS-CoV-2 recombinant proteins stimulate distinct cellular and humoral immune response profiles in samples from COVID-19 convalescent patients , 2021, Clinics.

[15]  D. Altmann,et al.  The immunology of asymptomatic SARS-CoV-2 infection: what are the key questions? , 2021, Nature Reviews Immunology.

[16]  R. Sindhi,et al.  Immune Response in Severe and Non-Severe Coronavirus Disease 2019 (COVID-19) Infection: A Mechanistic Landscape , 2021, Frontiers in Immunology.

[17]  J. Schwenk,et al.  SARS-CoV-2–specific B- and T-cell immunity in a population-based study of young Swedish adults , 2021, Journal of Allergy and Clinical Immunology.

[18]  M. Allende,et al.  Dysregulated Immune Responses in COVID-19 Patients Correlating With Disease Severity and Invasive Oxygen Requirements , 2021, Frontiers in Immunology.

[19]  P. Dönnes,et al.  Robust humoral and cellular immune responses and low risk for reinfection at least 8 months following asymptomatic to mild COVID‐19 , 2021, Journal of internal medicine.

[20]  A. Fontanet,et al.  Evolution of antibody responses up to 13 months after SARS-CoV-2 infection and risk of reinfection , 2021, EBioMedicine.

[21]  Xilong Deng,et al.  Protective humoral and cellular immune responses to SARS-CoV-2 persist up to 1 year after recovery , 2021, Nature Communications.

[22]  C. Broder,et al.  Durability of SARS-CoV-2-specific T cell responses at 12-months post-infection , 2021, bioRxiv.

[23]  J. Sacks,et al.  Evaluation of sixteen ELISA SARS-CoV-2 serological tests , 2021, Journal of Clinical Virology.

[24]  H. Rammensee,et al.  SARS‐CoV‐2‐reactive T‐cell receptors isolated from convalescent COVID‐19 patients confer potent T‐cell effector function , 2021, European journal of immunology.

[25]  S. Crotty.  Hybrid immunity , 2021, Science.

[26]  Julia Niessl,et al.  T cell immunity to SARS-CoV-2 , 2021, Seminars in Immunology.

[27]  P. Dormitzer,et al.  BNT162b2 vaccine induces neutralizing antibodies and poly-specific T cells in humans , 2021, Nature.

[28]  Gavin J. D. Smith,et al.  Early induction of functional SARS-CoV-2-specific T cells associates with rapid viral clearance and mild disease in COVID-19 patients , 2021, Cell Reports.

[29]  J. Redón,et al.  Adaptive immune responses to SARS-CoV-2 in recovered severe COVID-19 patients , 2021, Journal of Clinical Virology.

[30]  Bjoern Peters,et al.  Immunological memory to SARS-CoV-2 assessed for up to 8 months after infection , 2021, Science.

[31]  P. Brodin.  Immune determinants of COVID-19 disease presentation and severity , 2021, Nature Medicine.

[32]  F. Verreck,et al.  Pulmonary MTBVAC vaccination induces immune signatures previously correlated with prevention of tuberculosis infection , 2021, Cell reports. Medicine.

[33]  Siew Kim Ong,et al.  Widely heterogeneous humoral and cellular immunity after mild SARS-CoV-2 infection in a homogeneous population of healthy young men , 2021, Emerging microbes & infections.

[34]  S. Jameson,et al.  T Cell Memory: Understanding COVID-19 , 2020, Immunity.

[35]  E. Postnikova,et al.  Clinical, laboratory, and temporal predictors of neutralizing antibodies to SARS-CoV-2 among COVID-19 convalescent plasma donor candidates. , 2020, The Journal of clinical investigation.

[36]  Guoping Zhao,et al.  Dynamic anti-spike protein antibody profiles in COVID-19 patients , 2020, International Journal of Infectious Diseases.

[37]  S. Mallal,et al.  Comprehensive analysis of T cell immunodominance and immunoprevalence of SARS-CoV-2 epitopes in COVID-19 cases , 2020, bioRxiv.

[38]  B. Graham,et al.  T cell immunity to SARS-CoV-2 following natural infection and vaccination , 2020, Biochemical and Biophysical Research Communications.

[39]  P. Gallian,et al.  Convalescent plasma therapy for B-cell–depleted patients with protracted COVID-19 , 2020, Blood.

[40]  Leo Swadling,et al.  T cells in COVID-19 — united in diversity , 2020, Nature Immunology.

[41]  P. Sopp,et al.  Broad and strong memory CD4+ and CD8+ T cells induced by SARS-CoV-2 in UK convalescent individuals following COVID-19 , 2020, Nature Immunology.

[42]  R. Cox,et al.  Not just antibodies: B cells and T cells mediate immunity to COVID-19 , 2020, Nature Reviews Immunology.

[43]  S. Mallal,et al.  Selective and cross-reactive SARS-CoV-2 T cell epitopes in unexposed humans , 2020, Science.

[44]  U. Reimer,et al.  SARS-CoV-2-reactive T cells in healthy donors and patients with COVID-19 , 2020, Nature.

[45]  Nguyen H. Tran,et al.  Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial , 2020, The Lancet.

[46]  Martin Linster,et al.  SARS-CoV-2-specific T cell immunity in cases of COVID-19 and SARS, and uninfected controls , 2020, Nature.

[47]  Sharon J Peacock,et al.  Pathophysiology, Transmission, Diagnosis, and Treatment of Coronavirus Disease 2019 (COVID-19): A Review. , 2020, JAMA.

[48]  Morten Nielsen,et al.  Robust T Cell Immunity in Convalescent Individuals with Asymptomatic or Mild COVID-19 , 2020, Cell.

[49]  A. Sette,et al.  Phenotype and kinetics of SARS-CoV-2-specific T cells in COVID-19 patients with acute respiratory distress syndrome , 2020, Science Immunology.

[50]  X. Tang,et al.  Clinical and immunological assessment of asymptomatic SARS-CoV-2 infections , 2020, Nature Medicine.

[51]  J. Greenbaum,et al.  Targets of T Cell Responses to SARS-CoV-2 Coronavirus in Humans with COVID-19 Disease and Unexposed Individuals , 2020, Cell.

[52]  Xinquan Wang,et al.  Detection of SARS-CoV-2-Specific Humoral and Cellular Immunity in COVID-19 Convalescent Individuals , 2020, Immunity.

[53]  M. Girardis,et al.  Marked T cell activation, senescence, exhaustion and skewing towards TH17 in patients with COVID-19 pneumonia , 2020, Nature Communications.

[54]  Zilong Lu,et al.  The clinical course and its correlated immune status in COVID-19 pneumonia , 2020, Journal of Clinical Virology.

[55]  Y. Yazdanpanah,et al.  Severe Acute Respiratory Syndrome Coronavirus 2−Specific Antibody Responses in Coronavirus Disease Patients , 2020, Emerging infectious diseases.

[56]  W. Carson.  Understanding COVID-19 , 2020, Use of Patented Traditional Chinese Medicine against COVID-19.

[57]  A. Hill,et al.  Activation-induced Markers Detect Vaccine-Specific CD4+ T Cell Responses Not Measured by Assays Conventionally Used in Clinical Trials , 2018, Vaccines.

[58]  Mario Recker,et al.  Identification of immune signatures predictive of clinical protection from malaria , 2017, PLoS Comput. Biol..

[59]  Alessandro Sette,et al.  A Cytokine-Independent Approach To Identify Antigen-Specific Human Germinal Center T Follicular Helper Cells and Rare Antigen-Specific CD4+ T Cells in Blood , 2016, The Journal of Immunology.

[60]  Morten Nielsen,et al.  Gapped sequence alignment using artificial neural networks: application to the MHC class I system , 2016, Bioinform..

[61]  S. Riley,et al.  Longevity and determinants of protective humoral immunity after pandemic influenza infection. , 2015, American journal of respiratory and critical care medicine.